Anaemia is extremely common in patients with chronic kidney disease (CKD). Causes are multifactorial but erythropoietin deficiency, iron deficiency or diminished availability and chronic inflammation are pre-eminent. For over two decades it has been possible to correct the anaemia of patients with CKD with combinations of iron therapy and erythropoiesis-stimulating agents (ESA) with relative ease. Results of recent studies, however, have indicated that haemoglobin targets need to be revised and that more consideration should be directed to individualised treatment dependent upon the patient’s haemoglobin response, ESA dosage and level of co-morbidity.
|Number of pages||16|
|Journal||British Journal of Cardiology|
|Issue number||SUPPL. 2|
|Publication status||Published - Aug 2011|